clinical study
Clinical validation
selection of patients
clinical development program
high-profile clinical studies
optimal treatment of patients
DiviTum assay
company
high profile clinical studies
large pool of patients
clinical trial success rates
novel treatments
critical clinical decision tool
CDK inhibitors
commercialization of DiviTum
validated DiviTum
drug developers
novel CDK inhibitor
development of new cancer drugs
TK
clinicians
cell cycle regulation
Europe
cell proliferation
ineffective treatments
payers
state-of-the-art assay kit - DiviTum
higher risk of regulatory failure
decreased risk of regulatory failure
cancer therapy
efficacy biomarker
feasibility study
current target
monitoring tools
better tools
potential responders
optimized cohort selection
Cyclin Dependent Kinase
gold standard predictive
improved utilization of current
research market segment
serum-based detection of Thymidine Kinase
shorter time
practiced approach
leading oncology institutes
costs
pharma companies
conducted SME Instrument Phase
activity
key enzyme
solid tumors
compelling scientific rationale
results